Dimegan

Quick links to important sections

Dimegan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dimegan

The pharmaceutical entity referred to by the trade name Dimegan is based on the active ingredient brompheniramine maleate, a synthetic compound classified as a first-generation antihistamine. It is a common component in multi-symptom preparations intended for the oral treatment of temporary upper respiratory symptoms.

Property Description
Active ingredient Brompheniramine maleate
Form Syrup, Oral Solution, Tablets (often extended-release)
Pharmacological class First-generation antihistamine (Alkylamine class)
Common use Symptomatic relief of upper respiratory allergies/colds
Origin Synthetic organic compound

Identity and Pharmacological Classification

The core component, brompheniramine maleate, is structurally classified within the alkylamine class of antihistamines. Its primary function is that of a Histamine H1 receptor antagonist, meaning it works by competitively blocking the action of histamine, a natural substance released during an allergic response. This mechanism is central to its use in managing allergy-related discomfort, a therapeutic approach clinically recognized for controlling immediate hypersensitivity symptoms.

Composition and Available Forms

Dimegan is frequently presented as a combination medicine for oral administration, designed to address multiple symptoms concurrently. These combination products typically include brompheniramine maleate paired with a nasal decongestant (like pseudoephedrine or phenylephrine) and sometimes an antitussive (like dextromethorphan). The drug is offered in various forms, including syrup, oral solution, and tablet preparations. This variety of forms, particularly the readily administered syrup and the sustained-action extended-release tablet, provides flexibility in managing symptoms.

Core Therapeutic Purpose and Action Profile

The medication’s general purpose is to provide effective symptomatic relief for the characteristic manifestations of allergic rhinitis and the common cold. By acting as an H1 antagonist, the drug helps alleviate key symptoms such as sneezing, runny nose, and itchy, watery eyes. The inherent anticholinergic property of brompheniramine contributes to a drying action that further aids in controlling excessive nasal secretions. This combined effect makes it a recognized solution for patients experiencing acute seasonal allergy discomfort.

Regulatory References

  1. Brompheniramine MedlinePlus Drug Information

What side effects are possible with Dimegan?

Possible Side Effects and Safety Information

Dimegan, containing brompheniramine maleate, has an official safety profile primarily characterized by effects on the central nervous system (CNS) and anticholinergic actions, consistent with its classification as a first-generation antihistamine. The information below is based strictly on government regulatory documents.


Adverse Reaction Scope

The most frequent adverse reactions documented in regulatory sources include sedation or drowsiness, dry mouth, dry nose, dry throat, dizziness, and a thickening of bronchial secretions. These are typically categorized as Common effects.

Other adverse reactions are listed across several System-Organ Classes, including Nervous System Disorders (e.g., disturbed coordination, tremor, irritability), Gastrointestinal Disorders (e.g., nausea, vomiting, constipation), Cardiovascular System Disorders (e.g., hypotension, palpitation), and Genitourinary System Disorders (e.g., urinary retention, difficult urination).

Serious adverse reactions, though documented as rare, include convulsions (seizures), severe hypotension, and certain blood dyscrasias (e.g., hemolytic anemia, agranulocytosis).


Population-Specific Safety Notes

Official labels emphasize safety considerations for specific groups:

  • Older Adults (Geriatric): This population is cited as being more likely to experience adverse effects such as confusion, severe sedation, dizziness, hypotension, and intensified anticholinergic effects like urinary retention.
  • Pediatric Patients: There is a heightened potential for paradoxical excitation (e.g., nervousness, hyperactivity) in small children. Antihistamines, in general, are not recommended for the sedation of children.

Safety-Related Restrictions

Regulatory documents advise caution for individuals with pre-existing conditions that may be aggravated by anticholinergic properties. These conditions include narrow-angle glaucoma, prostatic hypertrophy, stenosing peptic ulcer, and urinary bladder neck obstruction. Caution is also noted for patients with a history of bronchial asthma.


Regulatory Safety Summary

The regulatory safety profile establishes that the drug's most frequent risks are related to its central depressant and drying properties. The official label incorporates specific warnings concerning low-frequency, serious systemic events and defines limitations for use in individuals with conditions susceptible to anticholinergic effects. This structure ensures a comprehensive outline of documented risks, as required by health authorities.

Overdose and Emergency Response

The official documentation for brompheniramine maleate overdose describes a range of clinical manifestations, primarily involving the Central Nervous System (CNS) and the cardiovascular system. CNS effects may present as a spectrum from depression to excitation, potentially including tremors, hallucinations, and convulsions. Recognized anticholinergic signs of over-ingestion include dilated pupils, dry mouth, and difficulty urinating.

Overdosage is classified as potentially severe and life-threatening due to the documented risk of complications, such as seizures and serious heart rhythm disturbances. Infants and small children are specifically noted in regulatory warnings as a population with an elevated risk of severe outcomes, including death, following overdosage.

Emergency action is mandated when over-ingestion is known or suspected. Seek medical help right away and call the Poison Control Center immediately for instructions. If the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened, immediately call emergency services (e.g., 911). Management documented in regulatory sources is symptomatic and supportive, and may include procedures such as gastric lavage or the use of activated charcoal, and specific agents like short-acting barbiturates to control CNS hyperactivity.

Therapeutic Uses of Dimegan

What Dimegan Treats: Main Uses and Benefits

Dimegan is commonly used to provide symptomatic support against the various manifestations of allergic reactions. It is used in situations involving certain distressing symptoms and may assist with managing symptoms associated with acute or episodic changes caused by seasonal and year-round allergies. The medication is commonly used to help with symptom clusters that may become intense or disruptive, such as frequent sneezing, a runny nose, itchy, watery eyes, and itching of the nose or throat.


Relief from General Allergy Symptoms

This medication is applied across domains where additional symptomatic support is needed for these common allergy symptoms. It plays a role in managing symptoms related to heightened physiological activity, which contributes to easing the overall symptom load and supports the patient during episodes of heightened discomfort.

“Applied in scenarios where additional management of discomfort is required, this supportive relief helps patients cope more steadily with symptom fluctuations.”

Easing Nasal and Sinus Discomfort

When addressing specific symptom clusters, Dimegan is relevant in contexts marked by increased discomfort due to nasal or sinus congestion and pressure. It is often used during phases when symptoms become more noticeable and create noticeable physiological strain. This supportive relief can assist with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Supports Functional Stability

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Dimegan?

The official regulatory profile for Dimegan (brompheniramine maleate) strictly defines which populations may and may not use the medicine.


Absolute Contraindications

Dimegan is strictly prohibited for several patient groups. It must not be used by individuals with known hypersensitivity to brompheniramine or alkylamine antihistamines, nursing mothers, newborns, or premature infants. Use is also prohibited in patients who have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days, or in those with an acute asthmatic attack, severe hypertension, or severe coronary artery disease.


Conditional Use and Restrictions

Eligibility is restricted or requires caution in several conditions. Use requires caution in older adults (aged 60 and over) due to increased susceptibility to effects like sedation. Caution is also advised for patients with narrow-angle glaucoma, prostatic hypertrophy, stenosing peptic ulcer, or significant hepatic or renal impairment. Pediatric use is restricted: the medicine is generally not recommended for children under 6 years of age, and use in the third trimester of pregnancy is advised against.

What should I know about interactions with other medicines?

Interactions with other medicines and products


The interaction profile of Dimegan, based on its active ingredient brompheniramine maleate, is defined by its potential for pharmacodynamic potentiation with other substances. The most severe regulatory restriction involves contraindicated combinations with specific classes of drugs.

Contraindicated and Restricted Combinations

Classification Official Regulatory Documentation
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs), including isocarboxazid, phenelzine, and tranylcypromine, are strictly prohibited for co-administration.
Timing-based Rule Brompheniramine must not be used concurrently with an MAOI or within 14 days of stopping therapy with an MAOI.

Pharmacodynamic and Exposure Interactions

Classification Official Regulatory Documentation
CNS Depressant Additive Effect Central Nervous System (CNS) Depressants, such as sedatives, hypnotics, tranquilizers, and opioid analgesics, have an additive effect, increasing the risk of documented drowsiness and impairment.
Alcohol Interaction The consumption of alcohol is officially noted to intensify the CNS depressant effects of the medicine.
Anticholinergic Potentiation Other anticholinergic drugs may result in additive adverse effects from cholinergic blockade, including increased drying effects.

Population-Specific Notes

The regulatory profile notes that the geriatric population may be more susceptible to the interaction-related effects, particularly CNS depression. The potential for reduced clearance and drug accumulation is also noted for patients with hepatic or renal impairment.

Mechanism of Action

How Dimegan Works

Dimegan's pharmacodynamic action is centered on its role as a competitive antagonist at the H1 histamine receptor. This mechanism blocks the endogenous neurotransmitter histamine from binding to and activating these receptors, which are widely expressed on effector cells, including those lining blood vessels. This receptor blockade modifies the intracellular cascade, leading to the physiological consequence of reduced blood vessel permeability and subsequent decreased plasma leakage into surrounding tissues.

Additionally, the drug exhibits a secondary antagonistic action at certain muscarinic acetylcholine receptors within the cholinergic system. This interaction dampens parasympathetic signaling sequences that regulate glandular function, resulting in a reduction in the flow of secretions from glands, particularly in the upper respiratory tract. The drug engages both peripheral and central receptor populations, with the central action contributing to the modulation of signals in the brain that influence alertness.

Dosage and Administration Information

How to Use Dimegan: Official Administration Guidelines

Dimegan is based on the active ingredient brompheniramine maleate and is intended for oral administration only, available as both Immediate-Release (IR) liquid/syrup and Extended-Release (ER) tablets or capsules. The proper use of the medicine is determined by its formulation, frequency, and specific handling requirements as outlined in regulatory documents.

Standard Dosing and Frequency

Age Group Immediate-Release (IR) Dose Frequency & Maximum
Adults (ge 12 years) 4 mg per dose Every 4 to 6 hours, not to exceed 24 mg in 24 hours
Children (6 to under 12) 2 mg per dose Every 4 to 6 hours, not to exceed 12 mg in 24 hours

Extended-Release formulations are typically dosed from 8 mg to 12 mg and are administered less frequently, generally every 12 hours or once daily (QD), depending on the product design.

Administration Requirements

The medicine may be taken with or without food; ingestion alongside food, milk, or water may help to minimize gastric irritation. For liquid forms, the dose must be measured precisely using the dosage cup or device provided by the manufacturer. Extended-release tablets and capsules must be swallowed whole and should not be crushed, broken, or chewed, as this compromises the intended timed-release mechanism.

For self-medication, use is generally intended for short-term symptom relief, and it should be discontinued if symptoms persist for more than seven days. Dosing for older adults must be approached cautiously, often starting at the lowest end of the recommended range.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dimegan

The information presented here is based on studies where the compound in Dimegan was studied for conditions characterized by fluctuating or episodic manifestations. The research describes group patterns and not individual predictions.

Research Evidence for Allergic Rhinitis Symptom Relief

What researchers studied The compound was studied for conditions characterized by fluctuating or episodic manifestations like allergic rhinitis in clinical trials, often randomized and placebo-controlled. These studies explored how symptoms evolved over short-term periods, typically a few weeks, in adults and adolescents. Researchers focused on patient-reported outcomes describing perceived discomfort, such as the severity of nasal and non-nasal symptoms. This research was relevant in trials assessing short-term or episodic symptom patterns.

What the studies reported Studies reported how symptoms evolved in the observed populations, focusing on measured differences in symptom scores between the active compound group and the placebo group. The findings describe patterns observed in the studies over the short-term trial period. Research also examined outcomes related to physical discomfort to help contextualize how patients reported their experience during periods of heightened symptom activity.

Research Evidence for Chronic Hives (Urticaria)

Research was studied for conditions associated with acute or disruptive episodes, such as chronic hives. Research examined outcomes related to physical discomfort by measuring the intensity of itching and the appearance of the rash or wheals. These investigations included short-term controlled trials and some longer-term descriptive reports, all of which were applied in research contexts involving fluctuating or unstable symptoms of the skin.

What Researchers and Patients Still Don't Know About Dimegan

Certainty remains low in several key areas of research, and the evidence quality varies across studies. The primary gaps include the lack of robust, long-term evidence. Limited information for long-term outcomes means we rely more on short-term data. Furthermore, comparative evidence is lacking against newer or complex therapies, and subgroup findings are uncertain for many specialized patient groups. Research is ongoing to provide more context, but studies help show what has been observed so far, highlighting what is known — and what is still uncertain.

Key Studies & References

  1. Dimegan® Product Monograph / Prescribing Information (Indicaciones Terapéuticas)

Frequently Asked Questions (FAQ)

Common questions about Dimegan (FAQ)

Q: What is the main reason doctors prescribe Dimegan?

Official product information describes Dimegan as being used for the temporary relief of symptoms associated with the common cold and various allergies, including hay fever. These symptoms typically include sneezing, a runny nose, and itchy or watery eyes.

Q: Is Dimegan considered a new type of medication?

Dimegan (brompheniramine) is classified as a first-generation antihistamine. This means it belongs to an older, established class of medications known for providing temporary symptom relief from allergies and colds.

Q: Does Dimegan help with pain or is it just for prevention?

Official regulatory information indicates that Dimegan is used for the temporary relief of symptoms, not for the prevention of the underlying condition. It is not labelled for use as a pain reliever.

Q: How quickly does Dimegan start to work after you begin taking it?

Studies and official product information indicate that the onset of action for this medication is typically around 30 minutes after taking an oral dose. This means the therapeutic effects usually begin to be noticeable within half an hour.

Q: Can Dimegan be taken with common over-the-counter pain relievers?

This drug is frequently sold in combination products that include common over-the-counter pain relievers. However, official information advises caution when combining any medication, and states that users should discuss specific risks with a healthcare professional.

Q: What are the most commonly reported side effects of Dimegan?

According to official regulatory documents, some of the most commonly reported side effects include drowsiness (sedation), dizziness, headache, and a drying effect on the mouth, nose, and throat. Nausea and the thickening of bronchial secretions are also noted.

Q: Is it normal to feel tired or dizzy when starting Dimegan?

Yes, official regulatory information lists drowsiness (sedation) and dizziness among the most frequent adverse reactions reported with this drug. These effects are part of the known profile of this type of medication.

Q: What kind of foods or drinks should people be cautious about while using Dimegan?

The official label advises caution regarding alcohol consumption. Alcohol is known to intensify the marked drowsiness effect caused by the medication.

Q: Is Dimegan safe for people who also have blood pressure issues?

Official product information notes that caution is required for patients who have heart disease or high blood pressure (hypertension). Use in those with severe or uncontrolled high blood pressure is typically contraindicated (a situation where the drug should not be used).

Q: What happens if I forget to take a dose of Dimegan?

Official regulatory guidance instructs users to take the medication exactly as directed by the label or by a healthcare professional. If a dose is missed, regulatory guidance indicates that users should avoid taking two doses close together or doubling the dose.

Q: Are there any known issues when taking Dimegan with supplements or vitamins?

While the regulatory label indicates that a healthcare professional should be informed about all products being taken to check for potential risks, specific interactions with non-drug supplements or vitamins are not detailed. General caution about combining substances is advised.

Q: What should I do if I accidentally take more Dimegan than intended?

Official warnings describe that in the event of an overdose, emergency medical help should be sought immediately. You can also contact a Poison Control Center right away for guidance.

Q: Can I take Dimegan if I am trying to become pregnant?

This drug is classified as Pregnancy Category C in regulatory documents. It is described as only administered to a pregnant woman when the benefit is considered clearly necessary. Use is generally advised to be avoided during the third trimester of pregnancy.

Q: Why does the packaging for Dimegan have a warning about heart issues?

Official warnings are present because the drug has the potential to cause adverse cardiovascular effects. These can include palpitations (fast or irregular heartbeat) and can worsen pre-existing conditions like heart disease or high blood pressure.

Q: What does the term 'contraindication' mean in the context of Dimegan?

The term contraindication, as used in official documents, means there is a specific condition or pre-existing situation where the drug should absolutely not be used. This is because the known risks outweigh any potential benefit in that context.

Q: Where can I find the official regulatory information about Dimegan's approval?

Official information and drug labels are published by government regulatory bodies, such as the FDA (available through DailyMed), and can be accessed via official health portals like the NIH (MedlinePlus).

Q: What are the signs that Dimegan might not be working for me?

Official guidelines indicate that users should discontinue use and consult a healthcare professional if their symptoms do not get better within seven days of beginning the medication. This guidance also applies if symptoms worsen or if they are accompanied by a fever.

Q: What kind of precautions are listed for Dimegan regarding sun exposure?

Official regulatory information lists photosensitivity (increased skin sensitivity to the sun) as one of the reported adverse reactions. This indicates that sun exposure precautions are often noted in relation to the medication.

Q: Does taking Dimegan at night change anything about its effects?

Due to the common side effect of drowsiness and sedation, taking the medication at bedtime is sometimes suggested. This timing can help minimize the potential for daytime impairment or drowsiness.

Q: What are the known serious side effects of Dimegan that I should be aware of?

Official regulatory documents list several serious adverse effects that may require medical attention, including confusion, hallucinations, and seizures. Irregular heartbeat (cardiac arrhythmias) and excessive nervousness are also noted.

Q: Is it a common concern that Dimegan might cause mood changes?

Yes, official documents list adverse reactions affecting the central nervous system that involve changes in mood or disposition. These can include feelings like nervousness, irritability, dysphoria, and euphoria.

Q: Are there any specific organs that Dimegan might affect over the long term?

Official product information notes that special caution is advised for patients with existing hepatic (liver) or renal (kidney) impairment. This is due to the potential for reduced drug clearance and accumulation.

Q: Why is consistent use important for a medicine like Dimegan?

The recommended dosing frequency (e.g., every four to six hours) is intended to maintain a steady concentration of the drug in the body. Consistent use is required to effectively block histamine receptors and provide continuous temporary symptom relief.

Q: Can Dimegan be split or crushed, according to the official instructions?

The official instructions for extended-release (ER) formulations state that these tablets and capsules must be swallowed whole. They should not be crushed, broken, or chewed, as this action interferes with the intended timed-release mechanism.

Q: Is Dimegan a preventative medication or a rescue medication?

Official documents indicate that this drug is used for the temporary relief of symptoms associated with allergies and the common cold. This classifies its use as symptomatic relief rather than prevention of the underlying condition.

Q: Is it possible for Dimegan to worsen my symptoms initially?

Official warnings note that in young children, this class of medication can sometimes produce paradoxical excitation instead of the expected drowsiness. This can result in temporary symptoms like nervousness or sleeplessness.

How should Dimegan be stored and disposed of?

Official Storage and Disposal Requirements

This information details the mandatory storage, stability, and disposal requirements for Dimegan as defined in regulatory documents. It does not contain administration instructions or therapeutic information.

Requirement Official Regulatory Statement
Storage Temperature Store the product at ambient temperature, below 25°C.
Light/Moisture Keep the medicine in its original outer carton to protect the contents from light.
Prohibited Conditions Do not refrigerate or freeze the product, as this may compromise stability.
In-Use Stability Discard any unused medicine 28 days after the first opening of the container.
Disposal Dispose of unused or expired product through an official drug take-back program or follow local governmental requirements to prevent environmental release.

These constraints ensure the chemical integrity of the medicine throughout its shelf life and guide users on environmentally appropriate disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dimegan found in:

A-Z Index: